Skip to content

Study · Observational study · n = 33 · 2016

6 results

Safety and effectiveness of daily teriparatide for osteoporosis in patients with severe stages of chronic kidney disease: post hoc analysis of a postmarketing observational study.

Nishikawa A, Yoshiki F, Taketsuna M, Kajimoto K, Enomoto H

Clinical interventions in aging15 Nov 2016Cited by 41 (Europe PMC)

PMID27895472 (opens in a new tab)PMCIDPMC5117886 (opens in a new tab)DOI10.2147/cia.s120175 (opens in a new tab)PepBankPUB-27895472
Read at sourcePubMedAsk about this study
Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

  1. 01HumanObservational studySafety outcome

    In women with severe CKD and osteoporosis, no serious adverse drug reactions were recorded during teriparatide treatment.

    In plain wordsIn women with severe kidney disease and osteoporosis, no serious drug reactions were recorded during teriparatide treatment.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    Not applicableSerious adverse drug reactions
    Study

    n = 33

    Outcome group
    Adverse events · Whole body
    Studied dose
    20 μg daily · subcutaneous · up to 24 monthsAs given in this study (human).

    Source sentences

    Summary
    No serious ADRs were recorded; a total of 4 ADRs were recorded for 4 of 33 patients.
    2 context sentences
    Summary · context
    This was a post hoc analysis of a postmarketing surveillance study that included patients with osteoporosis at high risk of fracture and stage 4 or 5 CKD.
    Summary · context
    Patients received subcutaneous teriparatide 20 μg daily for up to 24 months.
  2. 02HumanObservational studySafety outcome

    In women with severe CKD and osteoporosis, four adverse drug reactions occurred in four of 33 patients receiving teriparatide.

    In plain wordsIn women with severe kidney disease and osteoporosis, four patients had drug reactions during teriparatide treatment.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    Not applicableAdverse drug reactions
    Study

    n = 33

    Outcome group
    Adverse events · Whole body
    Studied dose
    20 μg daily · subcutaneous · up to 24 monthsAs given in this study (human).

    Measurements

    ADRs
    4 events
    teriparatide
    Patients with ADRs
    4 patients
    of 33

    Source sentences

    Summary
    No serious ADRs were recorded; a total of 4 ADRs were recorded for 4 of 33 patients.
    2 context sentences
    Summary · context
    This was a post hoc analysis of a postmarketing surveillance study that included patients with osteoporosis at high risk of fracture and stage 4 or 5 CKD.
    Summary · context
    Patients received subcutaneous teriparatide 20 μg daily for up to 24 months.
  3. 03HumanObservational studyEfficacy outcome

    During teriparatide treatment, no patients with stage 4 CKD developed new fractures.

    In plain wordsDuring teriparatide treatment, patients with stage 4 kidney disease had no new fractures.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    Not applicableNew fractures in stage 4 CKD
    Study

    n = 30

    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    20 μg daily · subcutaneous · up to 24 monthsAs given in this study (human).

    Source sentences

    Summary
    New fractures occurred in 1 patient with stage 5 CKD, but not in patients with stage 4 CKD.
    3 context sentences
    Summary · context
    A total of 33 patients with severe stages of CKD (stage 4, n=30; stage 5, n=3) were included.
    Summary · context
    This was a post hoc analysis of a postmarketing surveillance study that included patients with osteoporosis at high risk of fracture and stage 4 or 5 CKD.
    Summary · context
    Patients received subcutaneous teriparatide 20 μg daily for up to 24 months.
  4. 04HumanObservational studyEfficacy outcome

    During teriparatide treatment, one patient with stage 5 CKD developed a new fracture.

    In plain wordsDuring teriparatide treatment, one patient with stage 5 kidney disease had a new fracture.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    Not applicableNew fractures in stage 5 CKD
    Study

    n = 3

    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    20 μg daily · subcutaneous · up to 24 monthsAs given in this study (human).

    Measurements

    Patients with new fractures
    1 patient
    stage 5 CKD

    Source sentences

    Summary
    New fractures occurred in 1 patient with stage 5 CKD, but not in patients with stage 4 CKD.
    3 context sentences
    Summary · context
    A total of 33 patients with severe stages of CKD (stage 4, n=30; stage 5, n=3) were included.
    Summary · context
    This was a post hoc analysis of a postmarketing surveillance study that included patients with osteoporosis at high risk of fracture and stage 4 or 5 CKD.
    Summary · context
    Patients received subcutaneous teriparatide 20 μg daily for up to 24 months.
  5. 05HumanObservational studyEfficacy outcome

    In women with severe CKD and osteoporosis, BMD increased overall and in most individual patients during teriparatide treatment.

    In plain wordsIn women with severe kidney disease and osteoporosis, bone density increased overall during teriparatide treatment.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseBone mineral density
    Study

    n: not reported in source

    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    20 μg daily · subcutaneous · up to 24 monthsAs given in this study (human).

    Source sentences

    Summary
    Increases in BMD and P1NP levels were observed both overall and in most individual patients.
    2 context sentences
    Summary · context
    This was a post hoc analysis of a postmarketing surveillance study that included patients with osteoporosis at high risk of fracture and stage 4 or 5 CKD.
    Summary · context
    Patients received subcutaneous teriparatide 20 μg daily for up to 24 months.
  6. 06HumanObservational studyActivity measurement

    In women with severe CKD and osteoporosis, P1NP levels increased overall and in most individual patients during teriparatide treatment.

    In plain wordsIn women with severe kidney disease and osteoporosis, a bone formation marker increased overall during teriparatide treatment.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseP1NP levels
    Study

    n: not reported in source

    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    20 μg daily · subcutaneous · up to 24 monthsAs given in this study (human).

    Source sentences

    Summary
    Increases in BMD and P1NP levels were observed both overall and in most individual patients.
    2 context sentences
    Summary · context
    This was a post hoc analysis of a postmarketing surveillance study that included patients with osteoporosis at high risk of fracture and stage 4 or 5 CKD.
    Summary · context
    Patients received subcutaneous teriparatide 20 μg daily for up to 24 months.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.